Table 2.
Clinical Outcome of Patients Who Received Ceftolozane/Tazobactam and Those Who Received the Standard of Care
Clinical Outcome | Ceftolozane/Tazobactam (n = 47) |
Standard of Care (n = 50) |
P Value |
---|---|---|---|
Clinical outcome at EOIV | .10 | ||
Favorable clinical response | 41 (87) | 36 (72) | |
Clinical failure | 2 (4) | 9 (18) | |
ndeterminate | 4 (9) | 5 (10) | |
Clinical outcome at TOC | .01 | ||
Clinical cure | 34 (72) | 28 (56) | |
Clinical failure | 3 (6) | 15 (30) | |
Indeterminate | 10 (21) | 7 (14) | |
Clinical outcome at LFU | .028 | ||
Clinical cure | 33 (70) | 26 (52) | |
Clinical failure | 4 (9) | 15 (30) | |
Indeterminate | 10 (21) | 9 (18) | |
Mortality during the study | 3 (6) | 2 (4) | .67 |
Duration between last dose of study drug and death, d, median (range) | 17 (15–34) | 29 (28–29) | .77 |
Infection-related mortality | 0 (0) | 0 (0) | |
30-d all-cause mortality | 2 (4) | 2 (4) | >.99 |
Data are presented as No. of patients (%) unless otherwise specified.
Abbreviations: EOIV, end of intravenous therapy; LFU, late follow-up; TOC, test of cure.